A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors

Annals of Oncology

Volumn 15, Issue 8, 2004, Pages 1274-1283

  Marshall, J ^a   Chen, H ^b   Yang, D ^c   Figueira, M ^a   Bouker, K B ^a   Ling, Y ^a   Lippman, M ^c   Frankel, S R ^d   Hayes, D F ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d Genta Incorporated   (United States)

Author keywords

Advanced breast cancer; Bcl 2; Docetaxel; G3139; Solid tumors

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; CREATININE; DEXAMETHASONE; DOCETAXEL; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; TAXANE DERIVATIVE; THROMBOPLASTIN; TOPOTECAN; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLUID RETENTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LACRIMATION; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TAXOIDS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 4444355922     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh317     Document Type: Article

References (50)

1. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
2. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1: 19-30.
3. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
4. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
5. Pezzella F, Turley H, Kuzu I et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
6. Yan JJ, Chen FF, Tsai YC et al. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology 1996; 53: 6-11.
7. Bhargava V, Kell DL, van de Rijn M et al. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994; 145: 535-540.
8. Colombel M, Symmans F, Gil S. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993; 143: 390-399.
9. McDonnell T, Troncoso P, Brisbay S. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
10. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6: 1029-1035.
11. Tu SM, McConnell K, Marin MC et al. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells [published erratum appears in Cancer Lett 1996; 99: 247]. Cancer Lett 1995; 93: 147-155.
12. Koty PP, Zhang H, Levitt ML. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 1999; 23: 115-127.
13. Ziegler A, Luedke GH, Fabbro D et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997; 89: 1027-1036.
14. Zangemeister-Wittke U, Schenker T, Luedke GH et al. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998; 78: 1035-1042.
15. Monia BP, Sasmor H, Johnston JF et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 1996; 93: 15481-15484.
16. Mukhopadhyay T, Roth JA. Antisense regulation of oncogenes in human cancer. Crit Rev Oncol 1996; 7: 151-190.
17. Cotter FE, Johnson P, Hall P et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-3055.
18. Yang D, Ling Y, Amazan M et al. Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assoc Cancer Res 1999; 40: 729 (Abstr 4814).
19. Jansen B, Schlagbauer-Wadl H, Brown B et al. bcl-2.antisense therapy chemosensitizes human melanoma cells in SCID mice. Nat Med 1998; 4: 232-234.
20. Kitada S, Takayama S, De Riel K et al. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994; 4: 71-79.
21. Webb A, Cunningham D, Cotter F et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-1141.
22. Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
23. Jansen B, Schlagbauer-Wadl H, Brown BD et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4: 232-234.
24. Ochoa L, Kuhn J, Salinas R et al. G3139 downregulates the expression of Bcl-2 in patients with metastatic colorectal cancer treated with irinotecan (CPT-11). Proc Am Assoc Cancer Res 2001; 42: 848 (Abstr).
25. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
26. Rudin CM, Otterson GA, Mauer AM et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13: 539-545.
27. Marcucci G, Byrd JC, Dai G et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425-432.
28. Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728-1733.
29. Monzo M, Rosell R, Sanchez JJ et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786-1793.
30. Ling V, Charles F, Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 1992; 69: 2603-2609.
31. Sumantran VN, Ealovega MW, Nunez G et al. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2507-2510.
32. Tang SC, Shaheta N, Chernenko G et al. Expression of BAG-1 in invasive breast carcinomas. J Clin Oncol 1999; 17: 1710-1719.
33. Haldar S, Basu A, Croce C. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-233.
34. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
35. Raynaud FI, Orr RM, Goddard PM et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997; 281: 420-427.
36. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18: 1212-1219.
37. Piccart MJ, Klijn J, Paridaens R et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-3155.
38. Jansen B, Wacheck V, Heere-Ress E et al. Clinical, pharmacologic and pharmacodynamic study of Genasense (G3139, Bcl-2 antisense oligonucleotide) and Dacarbazine in patients with malignant melanoma. Proc Am Soc Clin Oncol 2001; 20: 357.
39. Morris MJ, Tong WP, Cordon-Cardo C et al. Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-683.
40. Yuen AR, Halsey J, Fisher GA et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999; 5: 3357-3363.
41. Adjei AA, Dy GK, Erlichman C et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003; 9: 115-123.
42. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28: 67-70.
43. Dragowska WH, Lopes de Menezes DE, Sartor J et al. Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis. Cytometry 2000; 40: 346-352.
44. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
45. Zhou D, Clarke P, Wang J et al. Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. J Biol Chem 1996; 271: 15194-15202.
46. van de Donk NW, Kamphuis MM, van Dijk M et al. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211-219.
47. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16: 3362-3368.
48. Silvestrini R, Veneroni S, Daidone M. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
49. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92: 34-41.
50. Benimetskaya L, Miller P, Benimetsky S et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 2001; 60: 1296-1307.